HUP0401575A2 - Új vinil-karbonsav-származékok és ezek alkalmazása cukorbetegség ellen és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Új vinil-karbonsav-származékok és ezek alkalmazása cukorbetegség ellen és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0401575A2
HUP0401575A2 HU0401575A HUP0401575A HUP0401575A2 HU P0401575 A2 HUP0401575 A2 HU P0401575A2 HU 0401575 A HU0401575 A HU 0401575A HU P0401575 A HUP0401575 A HU P0401575A HU P0401575 A2 HUP0401575 A2 HU P0401575A2
Authority
HU
Hungary
Prior art keywords
group
optionally
alkenyl
cycloalkyl
compounds
Prior art date
Application number
HU0401575A
Other languages
English (en)
Inventor
Lone Jeppesen
Paul Stanley Bury
John Patrick Mogensen
Ingrid Pettersson
Per Sauerberg
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HUP0401575A2 publication Critical patent/HUP0401575A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

(I) általános képletű vinil-karbonsav-származékok, ezek sói,szolvátjai, tautomerjei, polimorf módosulatai, sztereoizomerjei és asztereoizomerek keverékei, továbbá az ezen vegyületeket tartalmazógyógyszerkészítmények; eljárás e vegyületek és készítményekelőállítására, eljárás e vegyületek alkalmazásáragyógyszerkészítmények előállításánál, valamint eljárás e vegyületek éskészítmények gyógyászati alkalmazására, ahol az (I) általánosképletben X jelentése arilcsoport, fluorenilcsoport vagyheteroarilcsoport, amelyek bármelyike adott esetben egy vagy többhalogénatommal, hidroxilcsoporttal, cianocsoporttal, aminocsoporttal,alkil-amino-csoporttal, dialkil-amino-csoporttal, cikloalkil-amino-csoporttal, karboxilcsoporttal és/vagy adott esetben halogénezettalkilcsoporttal, cikloalkilcsoporttal, alkenilcsoporttal,alkinilcsoporttal, alkoxicsoporttal, cikloalkoxicsoporttal, alkil-szulfanil-csoporttal és/vagy 3-6 szénatomos cikloalkil-szulfanil-csoporttal; és/vagy adott esetben halogénatomot, perhalogén-metil-csoportot, perhalogén-metoxi-csoportot és/vagy 1-6 szénatomosalkilcsoportot viselő arilcsoporttal, ariloxicsoporttal, aril-szulfanil-csoporttal, acilcsoporttal, aralkilcsoporttal,aralkoxicsoporttal, heteroarilcsoporttal, heteroaralkilcsoporttal,heteroariloxicsoporttal és/vagy heteroaralkoxicsoporttalhelyettesített lehet; Y jelentése arilcsoport vagy heteroarilcsoport,amelyek bármelyike adott esetben egy vagy több, az X helyén szereplőcsoportok helyettesítőivel helyettesített lehet; vagy jelentésealkilcsoport, cikloalkilcsoport, alkenilcsoport, alkinilcsoport vagyalkeninilcsoport; Ar jelentése adott esetben egy vagy többhalogénatommal helyettesített ariléncsoport; Z jelentése oxigénatomvagy kénatom; Q jelentése -(CH2)n- általános képletű csoport, ahol njelentése 0, 1, 2 vagy 3; R1 jelentése hidrogénatom vagy halogénatom;vagy R1 jelentése alkilcsoport, cikloalkilcsoport, alkoxicsoport vagycikloalkoxicsoport, amelyek bármelyike adott esetben egy vagy többhalogénatommal, hidroxilcsoporttal, karboxilcsoporttal,aminocsoporttal és/vagy cianocsoporttal helyettesített lehet; és R2jelentése hidrogénatom, alkilcsoport, cikloalkilcsoport,alkenilcsoport, alkeninilcsoport vagy arilcsoport; azzal amegkötéssel, hogy X és Y jelentése egymástól függetlenülpiridilcsoporttól csak eltérő lehet. Ó
HU0401575A 2001-07-30 2002-07-05 Új vinil-karbonsav-származékok és ezek alkalmazása cukorbetegség ellen és ezeket tartalmazó gyógyszerkészítmények HUP0401575A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101154 2001-07-30
PCT/DK2002/000471 WO2003011807A1 (en) 2001-07-30 2002-07-05 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.

Publications (1)

Publication Number Publication Date
HUP0401575A2 true HUP0401575A2 (hu) 2004-11-29

Family

ID=8160643

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401575A HUP0401575A2 (hu) 2001-07-30 2002-07-05 Új vinil-karbonsav-származékok és ezek alkalmazása cukorbetegség ellen és ezeket tartalmazó gyógyszerkészítmények

Country Status (15)

Country Link
EP (1) EP1414778A1 (hu)
JP (1) JP2004536150A (hu)
KR (1) KR20040019087A (hu)
CN (1) CN1537093A (hu)
BR (1) BR0211414A (hu)
CA (1) CA2452665A1 (hu)
CZ (1) CZ2004133A3 (hu)
HU (1) HUP0401575A2 (hu)
IL (1) IL159547A0 (hu)
MX (1) MXPA04000891A (hu)
NO (1) NO20040389L (hu)
PL (1) PL366401A1 (hu)
RU (1) RU2004105956A (hu)
WO (1) WO2003011807A1 (hu)
ZA (1) ZA200400161B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091245B2 (en) 2002-09-05 2006-08-15 Novo Novdisk A/S Compounds, their preparation and use
RU2349582C2 (ru) * 2002-10-28 2009-03-20 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Новые соединения и их применение в качестве ppar-модуляторов
JP4584714B2 (ja) * 2002-10-28 2010-11-24 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規化合物、その調製および使用
ITRM20030305A1 (it) * 2003-06-20 2004-12-21 Sigma Tau Ind Farmaceuti Preparazione di nuovi derivati di acidi fenil o fenossialchil mono e dicarbossilici utili nel trattamento dell'iperglicemia e dell'ipertrigliceridemia tipiche del diabete del tipo ii.
ES2555031T3 (es) 2003-09-19 2015-12-28 Janssen Pharmaceutica N.V. Ácidos y análogos 4-((fenoxialquilo)tio)-fenoxiacéticos
AU2004285849B2 (en) 2003-09-19 2011-04-28 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
EA015717B1 (ru) 2005-12-22 2011-10-31 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
KR100693132B1 (ko) * 2006-06-23 2007-03-14 동해전장 주식회사 정션박스내에 삽입된 릴레이의 동작 검사 장치
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20120168303A1 (en) * 2011-01-05 2012-07-05 Sueng-Nien Kao Salt water activated emergency lighting device
CN103467406B (zh) * 2013-09-03 2014-12-17 浙江医药高等专科学校 卤素取代的四氮唑羧酸类化合物、其制备方法和用途
CN103467408B (zh) * 2013-09-03 2015-01-21 浙江医药高等专科学校 一类四氮唑羧酸类化合物及其用途
CN103467409B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 取代的四氮唑羧酸类化合物及其用途
CN103467405B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 一类四氮唑羧酸类化合物、其制备方法和用途
CN103467407B (zh) * 2013-09-03 2015-04-22 浙江医药高等专科学校 四氮唑羧酸类化合物及其用途
BR112023001048A2 (pt) 2020-07-22 2023-04-04 Reneo Pharmaceuticals Inc Agonista de ppar-delta cristalino
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098690B1 (en) * 1982-06-14 1987-09-09 Takeda Chemical Industries, Ltd. Vinyl carboxylic acid derivatives, their production and use
AU2652397A (en) * 1996-05-13 1997-12-05 Nippon Shinyaku Co. Ltd. Substituted ethylene compounds and drugs
KR20020005703A (ko) * 1999-04-20 2002-01-17 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 신규한 화합물, 그의 제법 및 용도
CA2395298A1 (en) * 2000-01-28 2001-08-02 Novo Nordisk A/S Propionic acid derivatives and their use in the treatment of diabetes and obesity

Also Published As

Publication number Publication date
CA2452665A1 (en) 2003-02-13
NO20040389L (no) 2004-01-29
PL366401A1 (en) 2005-01-24
ZA200400161B (en) 2004-08-18
BR0211414A (pt) 2004-08-17
CZ2004133A3 (cs) 2004-06-16
JP2004536150A (ja) 2004-12-02
KR20040019087A (ko) 2004-03-04
CN1537093A (zh) 2004-10-13
IL159547A0 (en) 2004-06-01
MXPA04000891A (es) 2004-05-21
WO2003011807A1 (en) 2003-02-13
EP1414778A1 (en) 2004-05-06
RU2004105956A (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
HUP0401575A2 (hu) Új vinil-karbonsav-származékok és ezek alkalmazása cukorbetegség ellen és ezeket tartalmazó gyógyszerkészítmények
HUP0401982A2 (hu) Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0102404A2 (hu) N-acilezett gyűrűs aminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
CY1117132T1 (el) Παραγωγο θειαζολιου
HUP0102425A2 (hu) Gyomorsav-elválasztást gátló imidazo-piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0002208A2 (en) Use of sulphonamide derivatives for the preparation of pharmaceutical compositions potentiating glutamate receptor function
PL275423A1 (en) Method of obtaining novel heterocyclic compounds
ATE218141T1 (de) Erythromycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
HUP0102851A2 (hu) Parazitaellenes artemizinin-származékok (endoperoxidok), eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
CA2155673A1 (en) N-alkyl-2-substituted atp analogues
HUP9802323A2 (hu) Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
HUP0202876A2 (hu) Karboxipeptidáz U gátló új vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
HUT45014A (en) Process for producing dihydropyridine derivatives and pharmaceutical compositions containing them
NZ332923A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
HUT72434A (en) Novel pyridone carboxylic acid derivatives, pharmaceutical compositions containing them and processes for their production
AU8997898A (en) Epoxysuccinamide derivatives
HUP0202379A2 (hu) Új vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
IE901314L (en) 2- substituted-n,n'-di(trimethoxybenzoyl)piperazines
HUP0204217A2 (en) Novel a-500359 derivatives
HUT75647A (en) Imidazolidinone derivatives and pharmaceutical compositions containing them, which are suitable for treament of senile dementia
ATE148128T1 (de) Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees